Trial Outcomes & Findings for Median Nerve Stimulation Pilot (NCT NCT04731714)

NCT ID: NCT04731714

Last Updated: 2023-10-05

Results Overview

The number of tics per minute is assessed by an expert rater blind to condition and time point. Mean tic frequency was compared in on vs. off 1-minute stimulation epochs on the rhythmic MNS day. This analysis replicates that of Study 3 in the Morera Maiquez et al 2020 citation, who reported tics in the last 40 seconds of the block to minimize carryover effects. A Mixed Models Analysis was used to test statistical significance; it included a factor for possible within-day carryover effect and used a logarithmic transformation for tic count. Data reported here have been back-transformed to the number of tics in the last 40 s of the stimulation blocks.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

34 participants

Primary outcome timeframe

During the 1-minute on and 1-minute off blocks of rhythmic MNS stimulation (total 4 blocks)

Results posted on

2023-10-05

Participant Flow

Participants were recruited through clinical referrals, referrals from the University of Nottingham research team, advertising and word of mouth. Recruitment began in June, 2021, with the first subject enrolled in July, 2021. Study completion was in April, 2022.

2 potential participants did not meet study inclusion criteria at screening and therefore were excluded prior to study arm assignment.

Participant milestones

Participant milestones
Measure
Experimental: Rhythmic MNS, Then Arrhythmic MNS
Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS. Rhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study. Arrhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Experimental: Arrhythmic MNS, Then Rhythmic MNS
Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS. Rhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study. Arrhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Overall Study
STARTED
16
16
Overall Study
Completed Study Visit 1
16
16
Overall Study
Completed Study Visit 2
16
16
Overall Study
COMPLETED
16
16
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Median Nerve Stimulation Pilot

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Experimental: Rhythmic MNS, Then Arrhythmic MNS
n=16 Participants
Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS. Rhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study. Arrhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Experimental: Arrhythmic MNS, Then Rhythmic MNS
n=16 Participants
Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS. Rhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study. Arrhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Total
n=32 Participants
Total of all reporting groups
Age, Continuous
36.81 years
STANDARD_DEVIATION 16.81 • n=5 Participants
31.25 years
STANDARD_DEVIATION 16.16 • n=7 Participants
34.03 years
STANDARD_DEVIATION 16.51 • n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
7 Participants
n=7 Participants
11 Participants
n=5 Participants
Sex: Female, Male
Male
12 Participants
n=5 Participants
9 Participants
n=7 Participants
21 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
n=5 Participants
15 Participants
n=7 Participants
31 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
White
15 Participants
n=5 Participants
14 Participants
n=7 Participants
29 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
16 participants
n=5 Participants
16 participants
n=7 Participants
32 participants
n=5 Participants

PRIMARY outcome

Timeframe: During the 1-minute on and 1-minute off blocks of rhythmic MNS stimulation (total 4 blocks)

Population: All participants in the study, 4 blocks for each participant (2 on, 2 off, in random order)

The number of tics per minute is assessed by an expert rater blind to condition and time point. Mean tic frequency was compared in on vs. off 1-minute stimulation epochs on the rhythmic MNS day. This analysis replicates that of Study 3 in the Morera Maiquez et al 2020 citation, who reported tics in the last 40 seconds of the block to minimize carryover effects. A Mixed Models Analysis was used to test statistical significance; it included a factor for possible within-day carryover effect and used a logarithmic transformation for tic count. Data reported here have been back-transformed to the number of tics in the last 40 s of the stimulation blocks.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Change in Tic Frequency From When MNS is Turned Off
Stimulation Off
12.1 Tic frequency (number of tics in 40 s)
Interval 9.3 to 15.8
Change in Tic Frequency From When MNS is Turned Off
Stimulation On
8.9 Tic frequency (number of tics in 40 s)
Interval 6.6 to 11.8

PRIMARY outcome

Timeframe: During the 1-minute on and 1-minute off blocks of rhythmic MNS stimulation (total 4 blocks)

Population: All participants in the study, 4 blocks for each participant (2 on, 2 off, in random order)

Severity is rated on a 5-point scale for each occurrence of any tic. The scale is the Intensity item from the Yale Global Tic Severity Scale \[YGTSS\], which uses integer scores from 0 (no tics) to 5 (severe intensity). Mean tic severity was compared in on vs. off 1-minute stimulation epochs on the rhythmic MNS day. This analysis replicates that of Study 3 in the Morera Maiquez et al 2020 citation.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Change in Tic Severity From When MNS is Turned Off
Stimulation Off
2.5 units on a scale
Interval 2.2 to 2.7
Change in Tic Severity From When MNS is Turned Off
Stimulation On
2.3 units on a scale
Interval 2.0 to 2.6

PRIMARY outcome

Timeframe: During 5-minute MNS stimulation on or off blocks 0, 5, 6, 7, 8 and 9

Population: All participants in the study

The number of tics per minute is assessed by an expert rater blind to condition and time point. Change in tic frequency from baseline (stimulation off) is compared between 5-minute MNS-on epochs on the rhythmic vs. the arrhythmic day. Subjects who do not complete both stimulation visits will not be included in this analysis. The hypothesized change is greater improvement (off to on) with rhythmic vs. arrhythmic stimulation. This analysis includes the first six 5-minute blocks on each MNS day (i.e., the blocks that all participants complete). MNS was administered throughout blocks 6 and 8 only. Tic frequency in block 0 (baseline, before any stimulation) on the same day was a covariate in the statistical model.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 5
85.8 Tic frequency (number of tics in 5 min.)
Interval 69.2 to 102.4
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 6
63.3 Tic frequency (number of tics in 5 min.)
Interval 46.5 to 80.2
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 7
74.2 Tic frequency (number of tics in 5 min.)
Interval 57.3 to 91.2
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 8
57.7 Tic frequency (number of tics in 5 min.)
Interval 40.8 to 74.5
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 9
65.0 Tic frequency (number of tics in 5 min.)
Interval 48.4 to 81.6
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 5
85.9 Tic frequency (number of tics in 5 min.)
Interval 69.7 to 102.1
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 6
61.8 Tic frequency (number of tics in 5 min.)
Interval 45.4 to 78.2
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 8
57.6 Tic frequency (number of tics in 5 min.)
Interval 41.2 to 74.0
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 9
68.4 Tic frequency (number of tics in 5 min.)
Interval 52.2 to 84.7
Change in Tic Frequency During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 7
67.5 Tic frequency (number of tics in 5 min.)
Interval 51.0 to 83.9

PRIMARY outcome

Timeframe: During 5-minute MNS stimulation on or off blocks 0, 5, 6, 7, 8 and 9

Population: All participants in the study

Overall tic severity for each 5-minute block is rated once on a 5-point scale by an expert blind to condition and time point. The scale is the Intensity item from the Yale Global Tic Severity Scale \[YGTSS\], which uses integer scores from 0 (no tics) to 5 (severe intensity). Change in tic severity from baseline (stimulation off) is compared between 5-minute MNS-on epochs on the rhythmic vs. the arrhythmic day. Subjects who do not complete both stimulation visits will not be included in this analysis. The hypothesized change was greater improvement (off to on) with rhythmic vs. arrhythmic stimulation. This analysis includes the first six 5-minute blocks on each MNS day (i.e., the blocks that all participants complete). MNS was administered throughout blocks 6 and 8 only. Tic frequency in block 0 (baseline, before any stimulation) on the same day was a covariate in the statistical model.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 8
3.0 units on a scale
Interval 2.7 to 3.3
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 9
3.1 units on a scale
Interval 2.8 to 3.3
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 6
3.2 units on a scale
Interval 2.9 to 3.4
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 8
3.1 units on a scale
Interval 2.8 to 3.3
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 9
3.1 units on a scale
Interval 2.8 to 3.3
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 5
3.4 units on a scale
Interval 3.1 to 3.6
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 6
3.2 units on a scale
Interval 2.9 to 3.5
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Arrhythmic Block 7
3.4 units on a scale
Interval 3.1 to 3.6
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 5
3.3 units on a scale
Interval 3.0 to 3.6
Change in Tic Severity During Rhythmic MNS (vs. Arrhythmic MNS)
Rhythmic Block 7
3.2 units on a scale
Interval 2.9 to 3.5

SECONDARY outcome

Timeframe: up to 20 minutes after the end of stimulation at each study visit up to 1 month

Population: All participants in the study

We compared the change in tic frequency from baseline, during each 1-minute-long period following the end of stimulation. Here baseline means the tic frequency during the last 5 minutes of MNS from the same day (block 8). Last observation carried forward was used for participants who had less than 20 minutes of data following block 8.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Change in Tic Severity After MNS Ends
Final Block Of Stimulation, rhythmic days
7.1 Tic frequency (tics per minute)
Interval 3.95 to 12.4
Change in Tic Severity After MNS Ends
20 minutes after stimulation, rhythmic days
12 Tic frequency (tics per minute)
Interval 5.0 to 17.75
Change in Tic Severity After MNS Ends
Final Block Of Stimulation, arrhythmic days
8 Tic frequency (tics per minute)
Interval 3.7 to 18.7
Change in Tic Severity After MNS Ends
20 minutes after stimulation, arrhythmic days
10 Tic frequency (tics per minute)
Interval 5.0 to 22.0

SECONDARY outcome

Timeframe: 5-25 minutes after the end of stimulation at each study visit up to 1 month

Population: All participants in the study

Clinical Global Impression of Improvement (CGI-I), rated by participant. The CGI-I is a 7-point scale ranging from 1 = very much improved to 7 = very much worse.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
CGI-I, Participant
Rhythmic Day
2.69 units on a scale
Standard Deviation 1.03
CGI-I, Participant
Arrhythmic Day
2.39 units on a scale
Standard Deviation 0.99

SECONDARY outcome

Timeframe: 5-25 minutes after the end of stimulation at each study visit up to 1 month

Population: All participants in the study

Clinical Global Impression of Improvement (CGI-I), rated by investigator. The CGI-I is a 7-point scale ranging from 1 = very much improved to 7 = very much worse.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
CGI-I, Investigator
Rhythmic Day
2.41 units on a scale
Standard Deviation 0.91
CGI-I, Investigator
Arrhythmic Day
2.56 units on a scale
Standard Deviation 1.01

SECONDARY outcome

Timeframe: 5-25 minutes after the end of stimulation at each study visit up to 1 month

Population: All participants in the study

Participant rates peak improvement experienced during the visit using the 4-point scale of the CGI (Unchanged or worse; Minimal - Slight improvement that doesn't decrease the overall impact of symptoms\*; Moderate - Decided improvement. Partial remission of symptoms; Marked - Vast improvement. Complete or nearly complete remission of all symptoms). \* = "Minimal" option anchor text slightly edited from original. The number provided is the number of participants who rated each visit as moderate or marked.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Rating of Therapeutic Effect Using the CGI Efficacy Index
Rhythmic Day
20 Participants
Rating of Therapeutic Effect Using the CGI Efficacy Index
Arrhythmic Day
23 Participants

SECONDARY outcome

Timeframe: At the end of each 5-min. MNS on or off block through block 9, at each study visit

Population: All participants in the study

Participant rates the maximal severity of any premonitory urges over the preceding minute, from 0=no premonitory urge to 100=maximally uncomfortable premonitory urge, using a Visual Analog Scale.

Outcome measures

Outcome measures
Measure
All Participants
n=32 Participants
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Arrhythmic Block 5
50.1 units on a scale
Interval 43.7 to 56.6
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Arrhythmic Block 6
36.5 units on a scale
Interval 30.0 to 43.1
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Arrhythmic Block 7
43.0 units on a scale
Interval 36.5 to 49.6
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Arrhythmic Block 9
38.4 units on a scale
Interval 31.9 to 45.0
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Rhythmic Block 5
50.3 units on a scale
Interval 43.8 to 56.8
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Rhythmic Block 6
34.1 units on a scale
Interval 27.6 to 40.7
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Rhythmic Block 7
45.5 units on a scale
Interval 39.0 to 52.1
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Rhythmic Block 8
32.8 units on a scale
Interval 26.3 to 39.4
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Rhythmic Block 9
40.5 units on a scale
Interval 34.1 to 47.0
VAS (Visual Analog Scale) Rating of Premonitory Urge Severity
Arrhythmic Block 8
32.0 units on a scale
Interval 25.4 to 38.7

SECONDARY outcome

Timeframe: 5-25 minutes after the end of stimulation at each study visit up to 1 month

Population: All study visits (2 per participant)

Participant rates peak discomfort experienced during the visit using the 4-point scale of the CGI: "Overall, today, how much DISCOMFORT did the stimulation cause? If discomfort is the wrong word, please substitute any negative effects or side effects of stimulation. (No discomfort; Discomfort noticeable, but not severe enough to concern me or to turn it off; Enough discomfort, impairment of functioning or social embarrassment that I would only keep it on if the benefit was considerable; Caused discomfort, impairment of functioning or social embarrassment to a degree that any treatment benefit was not worth leaving it on). The number provided is the number of visits where discomfort is rated as none or minimal.

Outcome measures

Outcome measures
Measure
All Participants
n=64 Visits
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Rating of Discomfort Using the CGI Efficacy Index (Edited)
57 Visits

SECONDARY outcome

Timeframe: 5-25 minutes after the end of stimulation at each study visit up to 1 month

Population: One guessed treatment assignment for each study visit (1 guess per visit, 2 visits per participant)

Participants guess at each study visit whether they received the active or sham MNS condition, and rate their certainty for that guess on a 0-3 scale (0 = pure guess, 3 = certain). The number reported here is the number of visits for which the participant guessed correctly (active vs. sham MNS).

Outcome measures

Outcome measures
Measure
All Participants
n=64 treatment guess on a given study visit
All participants in the study, including both those assigned to "sequence: rhythmic-arrhythmic" and those assigned to "sequence: arrhythmic-rhythmic"
Blindedness Assessment
Guessed correctly
30 treatment guess on a given study visit
Blindedness Assessment
Guessed incorrectly
34 treatment guess on a given study visit

Adverse Events

Experimental: Rhythmic MNS

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Experimental: Arrhythmic MNS

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Experimental: Rhythmic MNS
n=32 participants at risk
Rhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Experimental: Arrhythmic MNS
n=32 participants at risk
Arrhythmic median nerve stimulation: Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
Nervous system disorders
6.2%
2/32 • From enrollment through final study visit, up to 1 month
9.4%
3/32 • From enrollment through final study visit, up to 1 month
Nervous system disorders
Headache
3.1%
1/32 • From enrollment through final study visit, up to 1 month
0.00%
0/32 • From enrollment through final study visit, up to 1 month
Nervous system disorders
Itch
3.1%
1/32 • From enrollment through final study visit, up to 1 month
0.00%
0/32 • From enrollment through final study visit, up to 1 month

Additional Information

Kevin J. Black, M.D.

Washington University School of Medicine

Phone: 314-362-5041

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place